Financing Biotech Innovation
How is economic uncertainty creating funding constraints?
US biotech firms are at the forefront of innovation, driving scientific breakthroughs that have the potential to radically improve patient outcomes. But they are operating in an environment of significant uncertainty. Transformative technologies such as AI, a shifting US policy and regulatory environment, high interest rates and large funding requirements are adding to market pressures. Against this backdrop, a compelling commercialization strategy showing clear, future demonstrable asset value is as important as strong science.
In the past, a promising scientific or clinical concept could attract millions, but investors now demand validated clinical outcomes, a strong commercial story, and clear plans for market access and profitability. For biotechs launching a new asset, this means integrating commercial strategies early to avoid fundraising hurdles and maximize value.
The Financial Times, in partnership with Syneos Health, will bring together biotech, pharma and investors to discuss the challenges that emerging companies face when raising capital for drug development in today’s environment. Speakers will explore how to develop successful strategies to secure funding to ensure investment in drug innovation is a success.
IN-PERSON PASS
Access to sessions in-person, meet speakers and network with your industry peers. Breakfast and refreshments included.
DIGITAL PASS
Access to live talks, Q&A and video on demand. Network and connect with your peers through our online community.
Key Discussion Points
Commercial Planning
How should biotech companies think about balancing immediate clinical development needs with long-run commercialization objectives?
Early-Stage Valuations
What are the main valuation drivers being used today for how investors assess early clinical biotech companies? What key metrics are influencing early-stage valuations?
Policy and Regulatory Shifts
How is uncertainty from evolving policy and regulatory shifts changing the way biotechs evaluate their go-to-market pathways (partner, out-license, go-it-alone)?
“Data from Syneos speakers was insightful and the real world experience of industry speakers provided some great context.”
Past event delegate
We’re Here To Help
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice
